{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-073593","form_type":"8-K","ticker":"TRAW","cik":"0001130598","company_name":"Traws Pharma, Inc.","filed_at":"2026-06-12T21:25:19+00:00","discovered_at":"2026-06-12T21:26:00.281585+00:00","generated_at":"2026-06-12T21:26:37.920367+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Traws Pharma defers Phase 2a test of tivoxavir marboxil after UK MHRA review","bullets":["Phase 2a human influenza challenge study for TXM deferred due to negative UK MHRA review.","Tivoxavir marboxil retains potential for emergency bird flu use per CSO Pauza.","Company advancing backup influenza candidates with TXM's PK profile and no mutagenic potential.","Cash runway extends to Q1 2027; CEO confirms commitment to long-acting influenza antivirals."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-073593","json":"https://secwatch.observer/filing/0001104659-26-073593.json","markdown":"https://secwatch.observer/filing/0001104659-26-073593.md","text":"https://secwatch.observer/filing/0001104659-26-073593.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926073593/0001104659-26-073593-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1130598/000110465926073593/tm2617872d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T21:26:37.920367+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}